"We look forward to providing details on two key areas of focus for our company, animal health and Alzheimer's disease," said John C. Lechleiter, Ph.D., Lilly's chairman, president and chief executive officer. "We will review Elanco's strategy and its growth prospects. Since the acquisition of Novartis Animal Health in January, Elanco has emerged as a top-tier animal health company. In addition, investors can expect to learn more about Lilly's broad research efforts aimed at improving the diagnosis and treatment of Alzheimer's disease."